Type 2 Diabetes Treatment Approved to Reduce Risk of MACE

By August 28, 2017

The Food and Drug Administration (FDA) approval was based on data from the randomized, double-blind, placebo-controlled LEADER trial (n=9,340) that evaluated long-term effects of Victoza vs. placebo in patients with type 2 diabetes with high risk of major cardiovascular events (MACE).

Herpes Zoster Tied to Stroke Risk in Patients with Autoimmune Disease

February 03, 2017

For patients with autoimmune disease, herpes zoster tied to increased stroke risk in first 90 days